RG
AGIO icon

Redmile Group’s Agios Pharmaceuticals AGIO Stock Holding History

Redmile Group’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-681,165
Closed -$35M – 66
2017
Q2 		$35M Sell
681,165
-221,413
-25% -$11.3M 2.13% 15
2017
Q1 		$52.7M Buy
902,578
+164,127
+22% +$7.87M 3.42% 7
2016
Q4 		$30.8M Buy
738,451
+551
+0.1% +$28.9K 2.66% 14
2016
Q3 		$39M Buy
+737,900
New +$32.1M 3.1% 14
2014
Q4 		– Sell
-49,200
Closed -$3.02M – 55
2014
Q3 		$3.02M Buy
+49,200
New +$2.12M 0.35% 48
2013
Q4 		– Sell
-53,100
Closed -$1.49M – 57
2013
Q3 		$1.49M Buy
+53,100
New +$1.47M 0.22% 43

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Redmile Group's AGIO Position: Q3 2017 in Review

Redmile Group sold out of Agios Pharmaceuticals (AGIO) in Q3 2017, closing a stake of 681,165 shares — an estimated $35M sold.

Redmile Group first reported a position in AGIO in Q3 2013 and held it in 6 quarters. The position peaked at $52.7M in Q1 2017. 171 funds tracked by Wall St. Rank hold AGIO as of Q3 2017.

  • Redmile Group reported no remaining Agios Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Redmile Group sold 681,165 Agios Pharmaceuticals shares in Q3 2017, an estimated $35M.
  • Redmile Group first reported a position in Agios Pharmaceuticals in Q3 2013 and held it in 6 quarters.
  • Redmile Group's Agios Pharmaceuticals position peaked at $52.7M in Q1 2017.
  • 171 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2017.

Based on Redmile Group's 13F filing for Q3 2017, filed 14 Nov 2017.